The two compounds currently in clinical development are Nanbran Latte (JPH203) and JPH034.
Nanbulan lat is a novel small molecule compound that has been found to target LATl and inhibits its activity by competitively binding to amino acid pockets inside LAT1. It does not act on LAT2 expressed in normal cells and is known to specifically inhibit LATl.
Cryo-electron microscopy (cryo-EM) structural analysis of the Nanbran RAT (JPH203) competitively docking to LAT1.
Adapted from Y. Lee et al., Nat Commun., 2025, 16, 1635.
In addition, it has shown a unique biodistribution that is distributed in the liver, bile ducts, large intestine, etc. through multiple transporters, and is expected to be effective against certain solid tumors based on this characteristic. Currently, we are developing biliary tract cancer (second-line and first-line therapy) and colorectal cancer. In addition, with an eye on future expansion of indications, we are also embarking on non-clinical research targeting rare diseases.
On the other hand, JPH034 is characterized by its high intracerebral transferability, and we are promoting its development for secondary progressive multiple sclerosis and glioma without relapse, which are autoimmune diseases of the central nervous system.
In addition, we are also working on drug discovery studies for next-generation LATl inhibitors that aim to be best-in-class, and we have already identified candidate compounds. Through this, we will establish a new growth driver following Nanburan Rato and JPH034 and realize sustainable business expansion.
